FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313571830> ?p ?o ?g. }

• W4313571830 endingPage "349" @default.
• W4313571830 startingPage "349" @default.
• W4313571830 abstract "Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is often painful and can arise during or after the end of oncological treatments. They are mostly induced by platinum salts, taxanes, and immunotherapies. Their incidence is estimated between 19 and 85%. They can require a chemotherapy dose reduction or early termination. The European Society for Medical Oncology (ESMO) recommends high-concentration capsaicin patch (HCCP) in second line for the treatment of painful CIPN. This treatment induces a significative pain relief but only shown by low-powered studies. The objective of this study was to evaluate efficacy and tolerability of HCCP applications in CIPN. Methods: This monocentric observational retrospective real-world-data study of the CERCAN cohort took place in the Western Cancer Institute's Anaesthesiology and Pain Department at Angers, France. Independent pain physicians completed the CGIC (Clinician Global Impression of Change) for each patient who benefited from HCCP applications for painful CIPN starting from 1 January 2014 to 22 December 2021, based on the collected data after every patch application. Results: A total of 57 patients (80.7% women) was treated with HCCP for painful CIPN, and 184 applications were realized, consisting of 296 sessions. CGIC found an important or complete pain relief for 61 applications (33.2%, corresponding to 43.9% patients). We found less efficacy for platinum-salts-induced CIPN compared to others (p = 0.0238). The efficacy was significatively higher for repeated applications when HCCP was used in second line compared to third line (p = 0.018). The efficacy of HCCP was significatively higher starting the third application (p = 0.0334). HCCPs were mainly responsible for local adverse events found in 66.6% patients (65.1% burning or painful sensation, 21.1% erythema). Conclusion: HCCP applications in painful CIPN induce an important pain relief with a global satisfying tolerability." @default.
• W4313571830 created "2023-01-06" @default.
• W4313571830 creator A5015172846 @default.
• W4313571830 creator A5019168009 @default.
• W4313571830 creator A5034887042 @default.
• W4313571830 creator A5038697008 @default.
• W4313571830 creator A5044581431 @default.
• W4313571830 creator A5066524656 @default.
• W4313571830 creator A5078270448 @default.
• W4313571830 creator A5085493710 @default.
• W4313571830 creator A5087552869 @default.
• W4313571830 date "2023-01-05" @default.
• W4313571830 modified "2023-10-13" @default.
• W4313571830 title "Evaluation of 8% Capsaicin Patches in Chemotherapy-Induced Peripheral Neuropathy: A Retrospective Study in a Comprehensive Cancer Center" @default.
• W4313571830 cites W1978598856 @default.
• W4313571830 cites W1996512878 @default.
• W4313571830 cites W2048775455 @default.
• W4313571830 cites W2057662279 @default.
• W4313571830 cites W2060772141 @default.
• W4313571830 cites W2066582161 @default.
• W4313571830 cites W2071620144 @default.
• W4313571830 cites W2090715929 @default.
• W4313571830 cites W2104818454 @default.
• W4313571830 cites W2110324196 @default.
• W4313571830 cites W2114458368 @default.
• W4313571830 cites W2118820477 @default.
• W4313571830 cites W2126550106 @default.
• W4313571830 cites W2134902551 @default.
• W4313571830 cites W2143341124 @default.
• W4313571830 cites W2150112288 @default.
• W4313571830 cites W2164513741 @default.
• W4313571830 cites W2170259378 @default.
• W4313571830 cites W2221837786 @default.
• W4313571830 cites W2317160306 @default.
• W4313571830 cites W2523790029 @default.
• W4313571830 cites W2537315111 @default.
• W4313571830 cites W2569887568 @default.
• W4313571830 cites W2591345807 @default.
• W4313571830 cites W2606649147 @default.
• W4313571830 cites W2613929012 @default.
• W4313571830 cites W2746554938 @default.
• W4313571830 cites W2790265924 @default.
• W4313571830 cites W2792685576 @default.
• W4313571830 cites W2794596468 @default.
• W4313571830 cites W2890053128 @default.
• W4313571830 cites W2891102436 @default.
• W4313571830 cites W2925597476 @default.
• W4313571830 cites W2941730867 @default.
• W4313571830 cites W2954238247 @default.
• W4313571830 cites W2995306801 @default.
• W4313571830 cites W2998890161 @default.
• W4313571830 cites W3002274235 @default.
• W4313571830 cites W3021363784 @default.
• W4313571830 cites W3043680095 @default.
• W4313571830 cites W3045813318 @default.
• W4313571830 cites W3100349746 @default.
• W4313571830 cites W3130671713 @default.
• W4313571830 cites W3155443057 @default.
• W4313571830 cites W4226351559 @default.
• W4313571830 cites W4251622422 @default.
• W4313571830 doi "https://doi.org/10.3390/cancers15020349" @default.
• W4313571830 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36672298" @default.
• W4313571830 hasPublicationYear "2023" @default.
• W4313571830 type Work @default.
• W4313571830 citedByCount "1" @default.
• W4313571830 countsByYear W43135718302023 @default.
• W4313571830 crossrefType "journal-article" @default.
• W4313571830 hasAuthorship W4313571830A5015172846 @default.
• W4313571830 hasAuthorship W4313571830A5019168009 @default.
• W4313571830 hasAuthorship W4313571830A5034887042 @default.
• W4313571830 hasAuthorship W4313571830A5038697008 @default.
• W4313571830 hasAuthorship W4313571830A5044581431 @default.
• W4313571830 hasAuthorship W4313571830A5066524656 @default.
• W4313571830 hasAuthorship W4313571830A5078270448 @default.
• W4313571830 hasAuthorship W4313571830A5085493710 @default.
• W4313571830 hasAuthorship W4313571830A5087552869 @default.
• W4313571830 hasBestOaLocation W43135718301 @default.
• W4313571830 hasConcept C121608353 @default.
• W4313571830 hasConcept C126322002 @default.
• W4313571830 hasConcept C134018914 @default.
• W4313571830 hasConcept C143998085 @default.
• W4313571830 hasConcept C167135981 @default.
• W4313571830 hasConcept C170493617 @default.
• W4313571830 hasConcept C197934379 @default.
• W4313571830 hasConcept C2776694085 @default.
• W4313571830 hasConcept C2778375690 @default.
• W4313571830 hasConcept C2779289229 @default.
• W4313571830 hasConcept C2779901536 @default.
• W4313571830 hasConcept C2780051329 @default.
• W4313571830 hasConcept C2780073493 @default.
• W4313571830 hasConcept C555293320 @default.
• W4313571830 hasConcept C71924100 @default.
• W4313571830 hasConceptScore W4313571830C121608353 @default.
• W4313571830 hasConceptScore W4313571830C126322002 @default.
• W4313571830 hasConceptScore W4313571830C134018914 @default.
• W4313571830 hasConceptScore W4313571830C143998085 @default.
• W4313571830 hasConceptScore W4313571830C167135981 @default.
• W4313571830 hasConceptScore W4313571830C170493617 @default.

• next